Stephan Permann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stephan Permann has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Koeberle
Michael Popp Institute and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck 6020, Austria
3 shared publications - Anita Siller
Central Institute for Blood Transfusion and Immunology, University Hospital of Innsbruck, Tirol Kliniken GmbH, Innsbruck, Austria
3 shared publications - Danilo D'AVino
Department of Pharmacy, School of Medicine and Surgery University of Naples Federico II Naples Italy
3 shared publications - Lorenz Waltl
Michael Popp Institute and Center for Molecular Biosciences (CMBI) University of Innsbruck Innsbruck Austria
3 shared publications - Antonietta Rossi
Department of Pharmacy, School of Medicine and Surgery University of Naples Federico II Naples Italy
2 shared publications - Franz‐Lucas Haut
Institut für Chemie und Biochemie Organische Chemie Freie Universität Berlin Berlin Germany
2 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (59) , e76861
Reorganization of Innate Immune Cell Lipid Profiles by Bioinspired Meroterpenoids to Limit Inflammation
Lipidomics‐guided screening of unexplored natural product chemical space provides access to small molecules that globally reprogram cellular lipid profiles. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp . reshapes immune cell lipidomes, shifting them from pro‐inflammatory toward anti‐inflammatory and pro‐resolving mediators. Structural variation yielded derivatives that context‐dependently inhibit leukotriene biosynthesis to varying extents while upregulating pro‐resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, sphingosine‐1‐phosphate, and others in resting and activated innate immune cells in vitro, as well as in self‐resolving murine peritonitis and fibrosis in vivo. Mechanistically, meroterpenoids target 5‐lipoxygenase or 5‐lipoxygenase‐activating protein, promote 15‐lipoxygenase‐1 translocation to particulate sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid from neutral lipids to specific phospholipids while increasing free arachidonic acid levels. Furthermore, meroterpenoids reprogram immune cell lipid metabolism by reducing neutral lipid, triacylglycerol, and cholesteryl ester levels, a shift that correlates with a lower capacity for leukotriene biosynthesis and is phenocopied by inhibiting sterol‐O‐acyltransferase, which catalyzes cholesterol esterification for storage, and diacylglycerol acyltransferase‐1/2, which catalyze the final step in triacylglycerol biosynthesis. In conclusion, specific meroterpenoids exert anti‐inflammatory effects by rewiring lipid mediator biosynthesis through structure‐controlled switches in lipid mediator classes, and an unexpected link between lipogenesis and inflammation.
- 18 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (59) , e76861
Open AccessReorganization of Innate Immune Cell Lipid Profiles by Bioinspired Meroterpenoids to Limit Inflammation
Lipidomics‐guided screening of unexplored natural product chemical space provides access to small molecules that globally reprogram cellular lipid profiles. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp . reshapes immune cell lipidomes, shifting them from pro‐inflammatory toward anti‐inflammatory and pro‐resolving mediators. Structural variation yielded derivatives that context‐dependently inhibit leukotriene biosynthesis to varying extents while upregulating pro‐resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, sphingosine‐1‐phosphate, and others in resting and activated innate immune cells in vitro, as well as in self‐resolving murine peritonitis and fibrosis in vivo. Mechanistically, meroterpenoids target 5‐lipoxygenase or 5‐lipoxygenase‐activating protein, promote 15‐lipoxygenase‐1 translocation to particulate sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid from neutral lipids to specific phospholipids while increasing free arachidonic acid levels. Furthermore, meroterpenoids reprogram immune cell lipid metabolism by reducing neutral lipid, triacylglycerol, and cholesteryl ester levels, a shift that correlates with a lower capacity for leukotriene biosynthesis and is phenocopied by inhibiting sterol‐O‐acyltransferase, which catalyzes cholesterol esterification for storage, and diacylglycerol acyltransferase‐1/2, which catalyze the final step in triacylglycerol biosynthesis. In conclusion, specific meroterpenoids exert anti‐inflammatory effects by rewiring lipid mediator biosynthesis through structure‐controlled switches in lipid mediator classes, and an unexpected link between lipogenesis and inflammation.
- Open Access
- 1 July 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (9) , 6099-6128
Tocotrienol metabolites redirect lipid mediator production in innate immune cells towards inflammation resolution
- 1 July 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (9) , 6099-6128
Open AccessTocotrienol metabolites redirect lipid mediator production in innate immune cells towards inflammation resolution
- Open Access
Reorganization of innate immune cell lipid profiles by bioinspired meroterpenoids to limit inflammation
Lipidomics-guided screening of unexplored chemical space in natural products provides access to small molecules capable of modifying cellular lipid profiles on a global scale. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp . shapes the lipid profile of immune cells, favoring anti-inflammatory and pro-resolving over pro-inflammatory lipid mediators. Structural variation revealed derivatives that inhibit leukotriene biosynthesis to varying extents while differentially upregulating pro-resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, and sphingosine-1-phosphate, along with other mediators, both in resting and activated innate immune cells in vitro and in self-resolving murine peritonitis in vivo . Mechanistically, meroterpenoids target 5-lipoxygenase or 5-lipoxygenase-activating protein, promote the translocation of 15-lipoxygenase-1 to cytoplasmatic sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid (AA) from neutral lipids to specific phospholipids, while increasing the total concentration of free AA. Furthermore, meroterpenoids reprogram lipid metabolism in immune cells, decreasing the levels of neutral lipids, triacylglycerols, and cholesteryl esters. This shift correlates with a reduced capacity for leukotriene biosynthesis and is mimicked by the inhibition of sterol-O-acyltransferase and diacylglycerol acyltransferase-1/2. In conclusion, specific meroterpenoids exert anti-inflammatory effects by intervening in lipid mediator biosynthesis, prompting structure-controlled switches in lipid mediator classes, among others, through an unexpected link between lipogenesis and inflammation.
Open AccessReorganization of innate immune cell lipid profiles by bioinspired meroterpenoids to limit inflammation
Lipidomics-guided screening of unexplored chemical space in natural products provides access to small molecules capable of modifying cellular lipid profiles on a global scale. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp . shapes the lipid profile of immune cells, favoring anti-inflammatory and pro-resolving over pro-inflammatory lipid mediators. Structural variation revealed derivatives that inhibit leukotriene biosynthesis to varying extents while differentially upregulating pro-resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, and sphingosine-1-phosphate, along with other mediators, both in resting and activated innate immune cells in vitro and in self-resolving murine peritonitis in vivo . Mechanistically, meroterpenoids target 5-lipoxygenase or 5-lipoxygenase-activating protein, promote the translocation of 15-lipoxygenase-1 to cytoplasmatic sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid (AA) from neutral lipids to specific phospholipids, while increasing the total concentration of free AA. Furthermore, meroterpenoids reprogram lipid metabolism in immune cells, decreasing the levels of neutral lipids, triacylglycerols, and cholesteryl esters. This shift correlates with a reduced capacity for leukotriene biosynthesis and is mimicked by the inhibition of sterol-O-acyltransferase and diacylglycerol acyltransferase-1/2. In conclusion, specific meroterpenoids exert anti-inflammatory effects by intervening in lipid mediator biosynthesis, prompting structure-controlled switches in lipid mediator classes, among others, through an unexpected link between lipogenesis and inflammation.